Cardiovascular Care for Women: The 10-Q Report and Beyond

Program Overview

Cardiovascular Care for Women: The 10-Q Report and Beyond

An American Journal of Cardiology and American Journal of Medicine Multi-Media Webcast

According to the The National Coalition for Women’s Health Research’s 10Q Report: Advancing women’s heart health through improved research, diagnosis, and treatment published in June 2011, cardiovascular disease (CVD), a term used to describe diseases of the heart or blood vessels, is the leading cause of death for women in the United States, causing more than 420,000 deaths among women annually. Experts estimate that one in two women will die of heart disease or stroke, compared with one in 25 women who will die of breast cancer. Despite the fact that more women than men die each year of heart disease, and that there are known sex differences in symptoms and treatment, medical treatment of women has not changed substantially nor has it resulted in appropriate research into the distinct sex differences that exist in CVD. Time is of the essence. CVD death rates are increasing for women under age 55, despite an overall decrease in death rates from CVD in recent years.

This multimedia webcast will address the challenges of clinical practice with regard to the role of female gender in the diagnosis and treatment of cardiovascular disease and to help answer questions about the 10 topics of concern in the 10Q Report. A panel of experts present emerging evidence-based data and exercise clinical decision making by incorporating clinical cases and panel discussions.

Target Audience

Cardiologists, internists, primary care providers and healthcare professionals responsible for the diagnosis, treatment or management of women with cardiovascular disease.

Educational Objectives

Upon completion of this activity, participants will be able to:

  1. Better recognize presenting features of women with cardiovascular disease, with specific reference to differences from men
  2. Design more effective strategies for primary and secondary cardiovascular disease prevention in women
  3. Provide optimal assessment and treatment of chest pain in women
  4. Minimize cardiovascular mortality in young women after procedures and heart attack

Faculty

Sharonne N. Hayes MD, FACC, FAHA
Women's Heart Clinic
Professor of Medicine & Cardiovascular Diseases
Mayo Clinic
Rochester, MN

Carl J. Pepine, MD, MACC
Professor, Division of Cardiovascular Medicine
University of Florida
Gainesville, FL
William C. Roberts, MD
Executive Director, Baylor Cardiovascular Institute
Baylor University Medical Center
Waco, TX

Nanette K. Wenger, MD, MACC, MACP, FAHA
Professor of Medicine (Cardiology) Emeritus
Emory University School of Medicine
Consultant, Emory Heart and Vascular Center
Atlanta, GA

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With

Sharonne N. Hayes MD, FACC, FAHA

Nothing to disclose.

Carl J. Pepine, MD, MACC

Grant/Research Support: Amarin Corporation; Amgen, Inc.; Amorcyte, Inc.; AstraZeneca; Baxter Healthcare; Cytori Therapeutics; Daiichi Sankyo Company Limited; Eli Lilly and Company; Gambro; Genentech; GlaxoSmithKline; Medtronics, Inc.; Mesoblast Limited; National Institutes of Health/National Heart Blood and Lung Institute;  sanofi-aventis.
Consultant: Amarin Corporation, Eli Lilly and Company, Mesoblast Limited, SLACK Incorporated.
William C. Roberts, MDSpeaker’s Bureau: Merck and Company

Nanette K. Wenger, MD, MACC, MACP, FAHA

Grant/Research Support: Abbott Laboratories; Gilead Sciences, Inc.; Merck and Company; National Heart and Blood Institute; Pfizer, Inc.
Consultant: Abbott Women’s Advisory Board; Amgen, Inc.; AstraZeneca; Gilead Sciences; Janssen Pharmaceuticals, Inc.; Merck and Company; Pfizer, Inc..

Planners, Managers, Reviewers: Vincent E. Friedewald, MD, Timothy Hayes, MD, Karen Overstreet, EdD, RPh, FACEHP, CCMEP, Sandy Breslow, and Jill McNair hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Peer Review

This enduring material has been peer-reviewed by the American Journal of Cardiology.

Accreditation Statement

The EOCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an educational grant from Gilead Sciences, Inc.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education and Gilead Sciences, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course details

  • AMA PRA Category 1 Credit(s)™: 2.00
  • Non-physician: 2.00
  • Course opens: May 15, 2013
  • Course expires: May 14, 2014

Please log in or register to take this Course.